Cynthia Ann Lucero-Obusan

Dr. Cynthia Ann Lucero-Obusan

Office of Public Health, United States Department of Veterans Affairs, Washington D.C., USA
+2
orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2000 in Chest
Verified
Journal Article
Closed access
MBMark Brantly
Mark Brantly
NANilo A. Avila
Nilo A. Avila
Vorasuk ShotelersukVorasuk Shotelersuk
Vorasuk Shotelersuk
Cynthia Ann Lucero-ObusanCynthia Ann Lucero-Obusan
Cynthia Ann Lucero-Obusan
MHMarjan Huizing
Marjan Huizing
WGWilliam A. Gahl
William A. Gahl

23 October 2020 in MMWR. Morbidity and Mortality Weekly Report
Verified
Journal Article
Closed access
JCJordan Cates
Jordan Cates
Cynthia Ann Lucero-ObusanCynthia Ann Lucero-Obusan
Cynthia Ann Lucero-Obusan
RDRebecca M. Dahl
Rebecca M. Dahl
PSPatricia Schirmer
Patricia Schirmer
SGShikha Garg
Shikha Garg
CCCristina V. Cardemil
Cristina V. Cardemil
This report describes the in-hospital death rate of hospitalized patients with COVID-19 in the Veterans Health Administration compared with that of patients with influenza.

1 January 2000 in Pediatric Research
Verified
Journal Article
Open access
PDF file
YAYair Anikster
Yair Anikster
Cynthia Ann Lucero-ObusanCynthia Ann Lucero-Obusan
Cynthia Ann Lucero-Obusan
JGJuanru Guo
Juanru Guo
MHMarjan Huizing
Marjan Huizing
Vorasuk ShotelersukVorasuk Shotelersuk
Vorasuk Shotelersuk
WGWilliam A Gahl
William A Gahl
Ocular nonnephropathic cystinosis, a variant of the classic nephropathic type of cystinosis, is an autosomal recessive lysosomal storage disorder characterized by photophobia due to corneal cystine crystals but absence of renal disease. We determined the molecular basis for ocular cystinosis in four individuals. All had mutations in the cystinosis gene CTNS, indicating that ocular cystinosis is allelic with classic nephropathic cystinosis. The ocular cystinosis patients each had one severe mutation and one mild mutation, the latter consisting of either a 928 G→A (G197R) mutation or an IVS10–3 C→G splicing mutation resulting in the insertion of 182 bp of IVS10 into the CTNS mRNA. The mild mutations appear to allow for residual CTNS mRNA production, significant amounts of lysosomal cystine transport, and lower levels of cellular cystine compared with those in nephropathic cystinosis. The lack of kidney involvement in ocular cystinosis may be explained by two different mechanisms. On the one hand (e.g. the G197R mutation), significant residual cystinosin activity may be present in every tissue. On the other hand (e.g. the IVS10–3 C→G mutation), substantial cystinosin activity may exist in the kidney because of that tissue's specific expression of factors that promote splicing of a normal CTNS transcript. Each of these mechanisms could result in minimally reduced lysosomal cystine transport in the kidneys.

17 September 2021 in MMWR. Morbidity and Mortality Weekly Report
Verified
Journal Article
Open access
KBKristina L. Bajema
Kristina L. Bajema
Cynthia Ann Lucero-ObusanCynthia Ann Lucero-Obusan
Cynthia Ann Lucero-Obusan
COVID-19 mRNA vaccine effectiveness among U.S. veterans remains high, even during Delta variant spread.

10 December 2021 in MMWR. Morbidity and Mortality Weekly Report
Verified
Journal Article
Open access
KBKristina L. Bajema
Kristina L. Bajema
Cynthia Ann Lucero-ObusanCynthia Ann Lucero-Obusan
Cynthia Ann Lucero-Obusan
This report describes vaccine effectiveness in preventing COVID-19-associated hospitalizations among U.S. veterans.

1 September 2012 in Kidney International
Verified
Journal Article
Open access
KEKatherine D. Ellingson
Katherine D. Ellingson
RPRakhee S. Palekar
Rakhee S. Palekar
Cynthia Ann Lucero-ObusanCynthia Ann Lucero-Obusan
Cynthia Ann Lucero-Obusan
KKKatherine M. Kurkjian
Katherine M. Kurkjian
SCShua J. Chai
Shua J. Chai
PPPriti R. Patel
Priti R. Patel
In 2007 the Maryland Medical Examiner noted a potential cluster of fatal vascular access hemorrhages among hemodialysis patients, many of whom died outside of a health-care setting. To examine the epidemiology of fatal vascular access hemorrhages, we conducted a retrospective case review in District of Columbia, Maryland, and Virginia from January 2000 to July 2007 and a case–control study. Records from the Medical Examiner and Centers for Medicare and Medicaid Services were reviewed, from which 88 patients were identified as fatal vascular access hemorrhage cases. To assess risk factors, a subset of 20 cases from Maryland was compared to 38 controls randomly selected among hemodialysis patients who died from non-vascular access hemorrhage causes at the same Maryland facilities. Of the 88 confirmed cases, 55% hemorrhaged from arteriovenous grafts, 24% from arteriovenous fistulas, and 21% from central venous catheters. Of 82 case-patients with known location of hemorrhage, 78% occurred at home or in a nursing home. In the case–control analysis, statistically significant risk factors included the presence of an arteriovenous graft, access-related complications within 6 months of death, and hypertension; presence of a central venous catheter was significantly protective. Psychosocial factors and anticoagulant medications were not significant risk factors. Effective strategies to control vascular access hemorrhage in the home and further delineation of warning signs are needed.